Texas University Podcasts This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

CDK 4/6 Inhibitors in Treating Breast Cancer
Debu Tripathy, MD, Professor and Chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center explains how CDK 4/6 inhibitors are being integrated into breast cancer... Author: obr Added: 07/02/2019 (Source: Oncology Tube)
Source: Oncology Tube - July 2, 2019 Category: Cancer & Oncology Source Type: podcasts

ImPassion130 Trial Outcomes
Debu Tripathy, MD, Professor and Chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center shares the results of ImPassion130, a phase III study adding atezolizum... Author: obr Added: 07/02/2019 (Source: Oncology Tube)
Source: Oncology Tube - July 2, 2019 Category: Cancer & Oncology Source Type: podcasts

MONALEESA-7 Trial Outcomes in Premenopausal Breast Cancer
Debu Tripathy, MD, Professor and Chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center provides the outcomes of the MONALEESA-& trial in premenopausal breast ... Author: obr Added: 07/02/2019 (Source: Oncology Tube)
Source: Oncology Tube - July 2, 2019 Category: Cancer & Oncology Source Type: podcasts

Toxicity Of Nivolumab & Ipilimumab: Were Still Learning How To Leverage These Treatments In The Pre-Operative Setting
Tina Cascone MD Of The University of Texas MD Anderson Cancer Center Discusses Toxicity Of Nivolumab & Ipilimumab: Were Still Learning How To Leverage These Treatments In The Pre-Operative Setting. ... Author: Annual-Meeting Added: 06/06/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 6, 2019 Category: Cancer & Oncology Source Type: podcasts

Results Of NEOSTAR Study: Study Looked At Neoadjuvant Nivolumab Or Nivolumab Plus Ipilimumab For Resectable NSCLC
Tina Cascone MD Of The University of Texas MD Anderson Cancer Center Discusses Results Of NEOSTAR Study: Study Looked At Neoadjuvant Nivolumab Or Nivolumab Plus Ipilimumab For Resectable NSCLC. ... Author: Annual-Meeting Added: 06/06/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 6, 2019 Category: Cancer & Oncology Source Type: podcasts

What Can You Do About Rising Colorectal Cancer Rates
Scott Kopetz M.D., PhD., FACP Associate Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX Dis... Author: Cancer-News Added: 04/18/2019 (Source: Oncology Tube)
Source: Oncology Tube - April 18, 2019 Category: Cancer & Oncology Source Type: podcasts

Understanding Early Onset Colorectal Cancer
Scott Kopetz M.D., PhD., FACP Associate Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX Dis... Author: Cancer-News Added: 04/18/2019 (Source: Oncology Tube)
Source: Oncology Tube - April 18, 2019 Category: Cancer & Oncology Source Type: podcasts

Increasing Incidences In Colorectal Cancer
Scott Kopetz M.D., PhD., FACP Associate Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX Dis... Author: Cancer-News Added: 04/18/2019 (Source: Oncology Tube)
Source: Oncology Tube - April 18, 2019 Category: Cancer & Oncology Source Type: podcasts

Neoadjuvant Trials In Kidney Cancer
Jose Karam M.D., FACS Associate Professor in the Department of Urology at The University of Texas MD Anderson Cancer Center in Houston, Texas Discusses Neoadjuvant Trials In Kidney Cancer. At The Four... Author: kidneycancer Added: 04/17/2019 (Source: Oncology Tube)
Source: Oncology Tube - April 17, 2019 Category: Cancer & Oncology Source Type: podcasts